Transforming Atopic Dermatitis Treatment with Biodiversity-Based Topicals: Leveraging Microbial Ecosystems to Address the Root Cause of Immune-Mediated Skin Disease
- Demonstrating how a biodiversity-based topical with 13,000+ microbial species can modulate immune function and target the root cause of atopic dermatitis, supported by 142-patient clinical data
- Exploring regulatory and manufacturing challenges of advancing a microbiome-derived topical into phase 2 under Europe’s emerging multi-country licensing coordination model
- Addressing market differentiation and commercial strategy when a drug asset already exists in cosmetic form across 12 countries, and designing evidence to clearly separate drug vs cosmetic claims